David M. Nanus

Research interests

Publications

• Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01731

• Clinical features of neuroendocrine prostate cancer

  European Journal of Cancer · 2019 · 10.1016/j.ejca.2019.08.011

• A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-18-1912

• Patient derived organoids to model rare prostate cancer phenotypes

  Nature Communications · 2018 · 10.1038/s41467-018-04495-z

• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2015.64.2702

• Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

  Nature Medicine · 2016 · https://doi.org/10.1038/nm.4045

• Clonal evolution of chemotherapy-resistant urothelial carcinoma

  Nature Genetics · 2016 · 10.1038/ng.3692

• Integrative Clinical Genomics of Advanced Prostate Cancer

  Cell · 2015 · https://doi.org/10.1016/j.cell.2015.05.001

• Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response

  JAMA Oncology · 2015 · 10.1001/jamaoncol.2015.1313

• Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

  Cancer Research · 2014 · 10.1158/0008-5472.can-13-2876

• Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

  Neoplasia · 2013 · 10.1593/neo.121550

• Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer

  Neoplasia · 2013 · 10.1593/neo.121550

• Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

  Clinical Cancer Research · 2013 · 10.1158/1078-0432.ccr-13-0231

• Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

  European Urology · 2012 · 10.1016/j.eururo.2012.08.053

• Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

  Cancer Research · 2011 · 10.1158/0008-5472.can-11-1417

• Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

  Cancer Discovery · 2011 · https://doi.org/10.1158/2159-8290.cd-11-0130

• Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody

  Lab on a Chip · 2009 · 10.1039/b917959c

• Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/ neu –Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

  Journal of Clinical Oncology · 2007 · 10.1200/jco.2006.08.0994

• Low Incidence of Perioperative Chemotherapy for Stage III Bladder Cancer 1998 to 2003: A Report From the National Cancer Data Base

  The Journal of Urology · 2007 · 10.1016/j.juro.2007.03.101

• Low Incidence of Perioperative Chemotherapy for Stage III Bladder Cancer 1998 to 2003: A Report From the National Cancer Data Base

  The Journal of Urology · 2007 · 10.1016/j.juro.2007.03.101

• Phase I Trial of 177 Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.05.160

• Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer

  Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.09.154

• Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

  The Journal of Urology · 2003 · 10.1097/01.ju.0000091655.77601.0c

• Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma

  Journal of Clinical Oncology · 2000 · 10.1200/jco.2000.18.16.2972

• Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

  Nature Medicine · 1998 · 10.1038/nm0198-050

• Renal-Cell Carcinoma

  New England Journal of Medicine · 1996 · https://doi.org/10.1056/nejm199609193351207

Current projects

No projects listed.